sb 216763 has been researched along with Carcinoma, Ovarian Epithelial in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Czogalla, B; Fraungruber, P; Heidegger, H; Jeschke, U; Kaltofen, T; Mahner, S; Mayr, D; Preinfalk, V; Schwertler, S; Trillsch, F; Vattai, A; Vilsmaier, T | 1 |
1 other study(ies) available for sb 216763 and Carcinoma, Ovarian Epithelial
| Article | Year |
|---|---|
Potential of platinum-resensitization by Wnt signaling modulators as treatment approach for epithelial ovarian cancer.
Topics: Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; beta Catenin; Cadherins; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Movement; Diterpenes; Drug Resistance, Neoplasm; Epoxy Compounds; Female; Heterocyclic Compounds, 3-Ring; Humans; Indoles; Maleimides; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Ovarian Neoplasms; Phenanthrenes; Wnt Signaling Pathway | 2020 |